- Léčba intramuskulárním interferonem beta- 1a2013 | 1. lékařská fakulta
- Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?2017 | 1. lékařská fakulta
- No evidence of disease activity in patients receiving daclizumab versus intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis in the DECIDE study2017 | 1. lékařská fakulta
- Early magnetic resonance imaging predictors of clinical progression after 48months in clinically isolated syndrome patients treated with intramuscular interferon beta-1a2015 | 1. lékařská fakulta
- AMETYST - výsledky observační studie fáze IV sledující účinky intramuskulárně podávaného interferonu beta-1a u pacientů s klinicky izolovaným syndromem/ klinicky definitivní roztroušenou sklerózou2017 | 1. lékařská fakulta
- Intramuscular Interferon beta-1a, Azathioprine, and corticosteroid combination therapy in patients with relapsing-remitting multiple sclerosis: 5-year clinical efficacy resultsPublikace bez příslušnosti k fakultě
- Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE2018 | 1. lékařská fakulta
- Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study2012 | 1. lékařská fakulta
- Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study2012 | 2. lékařská fakulta
- Intramuscular Interferon Beta-1a in combination with azathioprine and low-dose steroids for relapsing-remitting multiple sclerosis: design and preliminary results of a two-year double-blind, randomized, placebo-controlled studyPublikace bez příslušnosti k fakultě
- Intramuscular Interferon Beta-1 in Combination with Azathioprine and Low-Dose Steroids for Relapsing-Remitting Multiple Sclerosis: Design and Preliminary Results of Two-Year Double-Blind, Randomized, Placebo-Controlled StudyPublikace bez příslušnosti k fakultě
- Intramuscular Interferon Beta-1a in combination with azathioprine and low-dose steroids for relapsing-remitting multiple sclerosis: design and preliminary results of a two-year double-blind, randomized, placebo-controlled study2001 | Fakulta tělesné výchovy a sportu
- Tolerability, treatment satisfaction and quality of life outcomes in stable multiple sclerosis patients switched from injectable therapies to auto injected intramuscular interferon beta 1a: The SFERA study2019 | Lékařská fakulta v Hradci Králové
- Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis2015 | 1. lékařská fakulta
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial2012 | 1. lékařská fakulta
- Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis2015 | 1. lékařská fakulta
- Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS2016 | 1. lékařská fakulta
- Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis2017 | 1. lékařská fakulta
- Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome2015 | 1. lékařská fakulta
- Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients2017 | 1. lékařská fakulta
- Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis2015 | 1. lékařská fakulta
- Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later2016 | 1. lékařská fakulta
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial2019 | 1. lékařská fakulta
- Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome2014 | 1. lékařská fakulta
- Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes2014 | 1. lékařská fakulta
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE) : a multicentre, randomised, 24-month, phase 3 trial2019 | 1. lékařská fakulta
- Lipid profiles are associated with lesion formation over 24 months in interferon-beta treated patients following the first demyelinating event2013 | 1. lékařská fakulta
- MRI correlates of disability progression in patients with CIS over 48 months2014 | 1. lékařská fakulta, Fakulta tělesné výchovy a sportu
- Pregnancy Experience : Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program2016 | 1. lékařská fakulta
- Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a2021 | 1. lékařská fakulta